Teva Pharmaceutical Industries Ltd (TEVA) Quote

Billionaire Stanley Druckenmiller Dumped His Entire Stake in Palantir and Has Piled Into This Suddenly Unstoppable Drug Stock for 3 Straight Quarters

https://finance.yahoo.com/news/billionaire-stanley-druckenmiller-dumped-entire-070600603.html

>>Another major step forward for Teva has been its vastly improved balance sheet. Under turnaround specialist CEO Kare Schultz, the company sold off non-core assets and reduced its operating expenses by billons per year. This prudent focus on spending has continued under current CEO Richard Francis. After tipping the scales with more than $35 billion in net debt following the Actavis deal, Teva now has less than $15 billion in net debt.

The other critical action undertaken by Francis has been to shift Teva toward novel-drug development. Though it's still a major player in generic drugs, developing brand-name therapies comes with higher margins and faster growth rates. Tardive dyskinesia drug Austedo looks to push for $2 billion in sales this year, which is up from $963 million in full-year sales in 2022. In other words, Teva has found its Copaxone replacement, and has plenty of other novel therapies ramping up sales and/or in the pipeline.

The cherry on top is that Teva Pharmaceutical Industries remains historically cheap despite its stock more than doubling over the trailing-two-year period. Its forward price-to-earnings ratio of 6.5 is well below other major pharmaceutical stocks and not fully indicative of the company's growth potential or ongoing turnaround.>>

Teva and Fosun Pharma Enter into a Strategic Partnership to Develop Novel Anti-PD1-IL2 Therapy (TEV-56278) in Immuno-Oncology

https://finance.yahoo.com/news/teva-fosun-pharma-enter-strategic-123000589.html

Truist Initiates Teva Pharmaceuticals (TEVA) Coverage with Buy, $25 Price Target

https://finance.yahoo.com/news/truist-initiates-teva-pharmaceuticals-teva-175009311.html

On Tuesday, May 27, an analyst from Truist Securities initiated coverage on Teva Pharmaceutical Industries Limited (NYSE:TEVA) with a Buy rating and a price target of $25.

Teva Pharma is an Israeli pharmaceutical company best known as one of the world’s largest manufacturers of generic drugs. In addition to generics, the company sells branded medicines and active pharmaceutical ingredients (APIs), offers contract manufacturing services, and operates an out-licensing platform through its affiliated company, Medis.

The Truist analyst believes the company’s strategy of building a portfolio of high-margin branded products while maintaining its core focus on generics is a key strength of its business model. This dual approach is expected to support sustainable and profitable growth in the years ahead.

The company has recently launched a $700 million cost-cutting initiative aimed at enhancing operational efficiency by reducing headcount and external spending. The analyst believes that this program will support margin improvement and help the company achieve its target of a 30% operating margin by 2027.

As a result of Teva’s continued focus on debt and cost reduction, as well as profitable growth, credit rating agencies Moody’s and Fitch upgraded the company’s corporate credit rating on May 15 and 20, respectively.

While we acknowledge the potential of TEVA as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an AI stock that is more promising than TEVA and that has 100x upside potential

Teva Reaffirms “Pivot to Growth” Strategy Progress with Launch of Acceleration Phase at 2025 Innovation and Strategy Day

Teva outlines acceleration path into a leading biopharma company

Innovative medicines franchise on track to exceed $5 billion by 2030, led by AUSTEDO® (deutetrabenazine), AJOVY® (fremanezumab), UZEDY® (risperidone) and late-stage pipeline with blockbuster potential

Reaffirming 2027 financial targets, including 30% operating profit margin, driven by innovative growth and transformation programs

TEL AVIV, Israel and PARSIPPANY, N.J., May 29, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceutical Industries Ltd. (NYSE and TASE: TEVA), is hosting today a 2025 Innovation & Strategy Day, to launch the acceleration phase of its “Pivot to Growth” strategy and to discuss portfolio priorities as it evolves into a global biopharmaceutical leader. The event, led by President and CEO Richard Francis and members of Teva’s executive management team, will outline the company’s strategy, progress and roadmap to deliver sustained shareholder value through 2030 and beyond.

Presentations begin at 8:30 a.m. Eastern Time and are expected to conclude at 12:30 p.m. Eastern Time. A live webcast of the event and presentation materials will be available on Teva's Investor Relations website at: https://ir.tevapharm.com/Events-and-Presentations.

Where We Are Today
Teva has completed Phase 1 of the Strategy: Return to Growth, delivering:

9 consecutive quarters of growth – fueled by strong momentum from key innovative growth drivers.

More than $2.3 billion in revenue in 2024 from Teva’s innovative portfolio: AUSTEDO®, AJOVY®, and UZEDY®.

Returning the generics business to growth with +5% in revenues across regions, and top 3 global portfolio with potential for five product launches by 2027.

“The past two years have been about returning to growth and building a solid foundation. Today, Teva is a fundamentally different company – more focused, more innovative, and more robust. I am proud that we have delivered on our commitments,” said Richard Francis, Teva’s President and CEO. “Now, we are accelerating our growth into a leading biopharma company with a strong innovative medicines franchise and a powerhouse generics and biosimilars portfolio.”

Delivering on Our Growth Engines
Teva’s innovative portfolio continues to drive strong performance and future potential. The company has announced its target to build a >$5 billion innovative medicines franchise by 2030, driven by AUSTEDO, AJOVY, UZEDY, and a robust pipeline of late-stage assets including olanzapine LAI, duvakitug, DARI, and emrusolmin.

AUSTEDO: Expected to exceed $2.5 billion in sales by 2027 and exceed $3 billion by 2030.

AJOVY: A globally established brand with presence across 43 countries and expected launches in 3 additional countries this year.

LAI schizophrenia franchise expected to have $1.5 billion to $2.0 billion in peak sales

UZEDY: Fastest growing LAI with >60% risperidone LAI market share captured.

Olanzapine LAI: Set to expand our LAI franchise - U.S. NDA filing expected in H2 2025.

Stepping Up Innovation
Teva’s late-stage pipeline includes multiple assets with proven mechanisms and blockbuster potential:

duvakitug (anti-TL1A): A potentially best-in-class treatment for inflammatory bowel disease, with potential expansion into additional indications with peak sales potential of up to $2-$5 billion.

DARI: A dual-action rescue inhaler for asthma, that could address a significant unmet need as a first ICS/SABA combination for both adult and pediatric patient populations, with peak sales potential of ~$1 billion.

olanzapine LAI: A differentiated long-acting injectable for schizophrenia, that we expect to build on the success of UZEDY and expand Teva’s LAI franchise.

emrusolmin: A potential first-in-class treatment for Multiple System Atrophy (MSA), a rare and fatal neurodegenerative disease that currently has no approved treatments, with peak sales potential of more than $2 billion.

TEV-‘408: Anti-IL-15 antibody granted fast-track designation by the U.S. Food and Drug Administration (FDA) to be evaluated for the treatment of celiac disease, with peak sales potential of more than $1 billion.

Sustaining Our Generics Powerhouse
Teva’s generics, biosimilars, and OTC business remains a stable, robust and cash-generating powerhouse. Teva continues to lead in generics globally, with a strong pipeline of complex generics and biosimilars.

13 biosimilars in the pipeline, with potential for 5 new launches planned by 2027.

Strategic focus on complex generics, biosimilars, and OTC to compensate gRevlimid by 2027.

Expanding on our $1.1 billion OTC business with a global portfolio of strong local and global brands, outperforming the market with double-digit growth.

Continued manufacturing transformation to enhance competitiveness and margins.

Focusing Our Business
Teva is accelerating shareholder value creation with reaffirmed its 2027 financial targets:

Revenue growth driven by innovative launches and stable generics business.

Operating margin expansion to 30% by 2027.

Free cash flow of >$2.7 billion in 2027 and >$3.5 billion by 2030.

Payment of debt down to 2x net leverage.

~$700 million in net savings through modernizing the organization and improving operational efficiencies, enabling reinvestment in R&D and commercial capabilities.

Moody's Investor Services Upgrades Teva Amid Continued Success of Pivot to Growth Strategy
Teva Pharmaceutical Industries Ltd

https://finance.yahoo.com/news/moodys-investor-services-upgrades-teva-221200201.html

TEL AVIV, Israel, May 15, 2025 (GLOBE NEWSWIRE) -- Teva Pharmaceuticals (NYSE and TASE: TEVA) today announced that Moody's Investor Services (“Moody's”) has raised the company's corporate credit rating to Ba1, outlook stable; from Ba2, outlook positive.

Moody's report cites the Company's strengths which include significant global scale, ongoing growth in the company’s branded franchises, stabilization of the company’s generics business, focus on debt reduction and resolution of various legal liabilities https://ratings.moodys.com/ratings-news/443085.

“This is a testament to the consistent performance of Teva as a result of the company’s Pivot to Growth strategy,” said Eli Kalif, Chief Financial Officer, Teva Pharmaceuticals. “This upgrade is expected to improve both our cost of debt, and our access to an enhanced base of investors.”

Today

TEVA, 10Q due 1/29

still busting new highs everyday LMFA😭

120%+ on my options from yesterday!


$TEVA

The market unfortunately is flooded with these auto immune products for crohns and ulcerative colitis. Buyer beware.

The market reaction thinks different.
Very different.

Unfortunately for TEVA the market is already flooded with crohns disease and auto immune drugs. They dont have a drug yet but even if they do it will be a competitive pricing blood bath on the market already well served.

Teva and Sanofi Announce Duvakitug (Anti-TL1A) Positive Phase 2b Results Demonstrating Best-in-Class Potential in Ulcerative Colitis and Crohn’s Disease

https://finance.yahoo.com/news/teva-sanofi-announce-duvakitug-anti-123000339.html

Here's another biotech that keeps following a pattern of popping and dropping. lol 7.22 to 7.37 today but looking like it wants to go up again and was over 11 less than 6 months ago.

Thank you...It IS a great plan...Looking forward to trying this elsewhere. =)

Eli Lilly ordered to pay $176.5 mln to Teva in U.S. migraine drug patent trial

Blake Brittain

https://finance.yahoo.com/news/eli-lilly-ordered-pay-176-213004418.html

Nov 9 (Reuters) - Eli Lilly & Co must pay Teva Pharmaceuticals International GmbH $176.5 million after a trial to determine whether its migraine drug Emgality infringed three Teva patents, a Boston federal court jury decided on Wednesday.

The jury agreed with Teva that Lilly's Emgality violated its rights in the patents, which relate to its own migraine drug Ajovy. Both drugs treat migraines by employing antibodies to inhibit headache-causing peptides.

The jury also found that Lilly infringed the patents willfully and rejected its argument that the patents were invalid.

A spokesperson for Lilly said the company was disappointed by the verdict but is confident that it will "ultimately prevail" in the case, and said the decision does not affect its ability to offer Emgality to patients.

A Teva spokesperson said the company is pleased with the decision and will "continue to vigorously defend its intellectual property rights."

Indianapolis-based Lilly earned over $577 million from Emgality sales worldwide last year, while Israel-based Teva made $313 million from Ajovy, according to company filings with the U.S. Securities and Exchange Commission.

Teva has said that expects its two branded drugs, Ajovy and Huntington's disease drug Austedo, to generate a combined $1.4 billion in revenue this year.

Teva sued Lilly over the patents in 2018. The same day Teva sued, the court dismissed two related Teva lawsuits seeking to block Emgality from coming onto the U.S. market.

Teva also filed a separate, ongoing patent lawsuit against Lilly in Massachusetts over Emgality last year. (Reporting by Blake Brittain in Washington Editing by David Bario and Deepa Babington)

4.25 $$$$Billion wow

Bought some 7's for this week (.36) and saw we popped in the AH to 8.40's. Can't exercise in the AH and wanted to lock in that almost 300% gain by shorting the shares directly in the AH and covering with my 7 calls but I've got no clue if that's how it works. lol Ever do anything like that?

It's not just a good plan ...

It's a great plan!

Once I got the hang of it, that's all I do and I've been doing it for years. I've gained so much confidence in how well it works such that I only use one stock symbol and go all-in using both my Individual and Retirement accounts.

The only caveat (which posed limits on what I could do years ago) was that one should (pronounced must) only trade stocks that have weekly options, which provides more opportunities to tweak the trades as the options come down in price quicker than they would if you were stuck with monthly expiration options. Using weekly options, I've had no trouble creating very high percentage gains at the end of every month and year.

I was born into a farmer family. My father had milk cows, and he also grew feed crops for those cows. That's a very smart way to run a farm because he didn't have to buy any feed crop from other farmers for the purpose of feeding his cows. Some of the grain that he harvested fed his cows, while the excess grain was sold to dairy farmers which didn't have sufficient land to grow all the feed that they needed. Bingo!

Buy all the stock you can afford. Choose one that is alive and well as shown by its pricing (feeding) habits. You know, like TEVA, as it goes up and down in relatively confined and predictable ranges so your stock might be assigned at the end of the first week or it might not in which case you sell Calls again during the next week, and maybe again during the following week. Hey, if you are going to own stock, at least milk it. If it gets assigned away at the end of the week, buy it back on the following Monday or a little later depending on how it's trending. You might get it cheaper than the price it was assigned at. Or buy that other milk cow you've been watching, then sell its Calls.

Smart and sounds like a good plan.
I've only bought calls and sometimes puts. Haven't sold calls or puts as I feel too new to options and don't want to mess up. I think I accidently sold something once and I noticed it immediately and I made sure I bought it right back.
I assume a 'covered call' is selling the call of the shares you own. Example Buy 1,000 shares of TEVA @ 8 you sell the weekly call of 8 (10 contracts) so if the stock goes down you make money on the option and if it goes up against you the shares balance a gain to what you could lose on selling the option.

Works for me ...

My favorite way of making money on stocks is to buy the shares then sell weekly Covered Calls against the stock week after week.

When finally assigned -- wash, rinse, repeat. That's a steady 52 paychecks every year.

This method even compounds: once assigned, there's more cash to buy more shares and sell more CCs.

However, there's one thing I wont do, which is to chase it downward when it appears to be trending that way. I'd rather just sit on cash and wait for a bottoming pattern.

Under 8 bucks again...

Looks like TEVA might have sat down at the dressing table. Looking forward to them beginning to apply some makeup. Do we wait for the lipstick?

One year later....

Well that would be a 100% gain from here.

Wow people here again?!? OK not really with 10 total posts in 2021 but....I expect a global settlement in 2022 will liven this place up.
With the beating the market took after FED I'm shocked we didn't break back down to 8. Was hoping we could BUST through that 8.5 and stay above but...at least it got above 8.60 for a little bit today. Looks like a range and had we won in court the ceiling would be 10.20's instead of 8.60....Settlement if favorable which I expect, should create a lot of POPS and DROPS but doubt we go back under 10 whenever that happens. Could see us touch 5's if overall market forces some others to have to sell to cover other stuff but should recover. I don't think were going to BK but I wouldn't doubt some 'rumors' spread to force a fire sale for a few days before an actual settlement.

TEVA. Narcan spray is huge WOOHOOOOOO

Weed oils do nothing for you it’s all bullshit. Oils cause seizures.

That’s why it’s probably still going down no money in weed. When you can grow it I can grow it it makes it worthless. All weed companies are going bankrupt.

Teva Israel enters medical cannabis market with new partnership

Reuters

https://www.reuters.com/world/middle-east/teva-pharm-enters-medical-cannabis-market-with-new-partnership-2021-12-26/

JERUSALEM, Dec 26 (Reuters) - (This December 26 story was corrected after company clarified that the deal is with Teva Israel)

The Israeli unit of drugmaker Teva Pharmaceutical Industries (TEVA.TA) said on Sunday it was entering the medical cannabis market by signing an exclusive and mutual collaboration agreement with another Israeli company, Tikun Olam-Cannbit (TKUN.TA).

Under the agreement, Tikun Olam-Cannbit will produce several medical cannabis products that are administered as oils. They will be marketed by Teva Israel to patients in Israel, the Palestinian Authority and, when the market opens, Ukraine, the company said.

Once Teva Israel receives all the required regulatory approvals, the companies will collaborate for 10 years and that could be extended by another nine years.

"Today, it is clear to many in the pharmaceutical industry and in the medical community that use of oils produced from specific cannabis strains may provide additional treatment options and respond to unaddressed medical needs of patients," said Yossi Ofek, chief executive of Teva Israel.

Do or die TEVA

Jan ‘21 $9 puts have 75% chance of expiring worthless per Stock Option Channel.

Opiods appears to had hundreds of thousands of deaths $TEVA

Should start moving after current pullback

Teva up you go $20

Hopefully, in 2021 they get their sheet together

$TEVA slowly coming to the realization they have to become more aggressive and pay down debt. Target 15-20 within 10-12 months

$TEVA https://www.calcalistech.com/ctech/articles/0,7340,L-3884172,00.html

TEVA buyout coming $25 Target price

TEVA $15 TARGET price today WOOHOOOOOOOOOO

TEVA $15 TARGET price today WOOHOOOOOOOOOO

I smell a takeover. Maybe CAH. TEVA hasn’t moved like this in years. The frat houses are loading up..

What happened to Teva today this sudden jump

TEVA looking better than before. Target for 2021 is 15-18

TEVA $15 TARGET PRICE WOOHOOOOOOOOOOOOOOO

Option time

$TEVA difficult to crack resistance @9.75

* * $TEVA Video Chart 11-05-2020 * *

Link to Video - click here to watch the technical chart video

$TEVA can break resistance over 9.05. Lifeless to say the least without any good news. It’s shameful management has no confidence and increase their Buyback of shares.

News; $TEVA 3 Top Stocks You Can Buy and Hold for the Next Decade

Successful stock investing requires you to have a long-term focus. Because the market sometimes crashes , you need at least a five-year time horizon when considering any stock investment. On the opposite end of the time horizon question, Warren Buffett has said that his favorite holding period...

Got this from TEVA - 3 Top Stocks You Can Buy and Hold for the Next Decade

ALERT! TEVA Charged For Generic Drugs Price-Fixing Probe

U.S. Poised to Charge Teva in Generic Drugs Price-Fixing Probe
Aug. 25, 2020, 2:16 PM

U.S. prosecutors are preparing to charge Teva Pharmaceutical Industries Ltd. with conspiring with competitors to raise prices for generic drugs, according to a person familiar with the matter.

The Justice Department is planning to charge Teva as soon as Tuesday after the company rebuffed a settlement that would have required paying a criminal penalty and admitting wrongdoing, said the person, who declined to be named because the matter is confidential.

A spokesperson for Teva, which is based in Israel, declined to comment.

https://news.bloomberglaw.com/pharma-and-life-sciences/u-s-poised-to-charge-teva-in-generic-drugs-price-fixing-probe

Recently

Drug firm bets it won't be charged

In the coming days, the Justice Department will decide whether to file criminal charges against one of the world's largest pharmaceutical companies suspected of colluding with rivals to inflate the prices of widely used drugs.

The company, Teva Pharmaceutical Industries, is betting that in the middle of a deadly pandemic, the Trump administration won't dare to come down hard on the largest supplier of generic drugs in the United States.

It is a high-stakes gamble that could affect millions of Americans who rely on Teva's dozens of inexpensive generic drugs, as well as its brand-name products like Copaxone, for multiple sclerosis, and Ajovy, for migraines. Teva officials say criminal charges could cripple the Israeli company and potentially leave it unable to sell drugs to federal programs like Medicare.

For years, the Justice Department and state prosecutors have been investigating what they describe as a conspiracy by pharmaceutical companies to increase the prices of popular drugs. The department has already extracted guilty pleas and $224 million in penalties from four other drug companies.

Lawyers for Teva, which prosecutors believe was deeply involved in the conspiracy, until recently had been holding settlement negotiations with officials in the Justice Department's antitrust division. But in April, the company all but walked away from the talks, according to people on both sides of the discussions.